GTS-21, a Nicotinic Agonist, Protects against Neocortical Neuronal Cell Loss Induced by the Nucleus Basalis Magnocellularis Lesion in Rats

Access this Article

Author(s)

Abstract

Effect of subchronically administered GTS-21 [3-(2, 4-dimethoxybenzylidene)-anabaseine dihydrochloride], a selective nicotinic agonist, on neuronal cell loss caused by nucleus basalis magnocellularis (nBM)lesion was studied in rats. After 2 weeks of bilateral nBM excitotoxic lesion, GTS-21 was orally administered once daily for 20 weeks. Neuronal cell loss was observed in layers 11-111 of the parietal cortex in the lesioned control rats. GTS-21 significantly attenuated the neuron loss in these layers. These results suggest that GTS-21 exhibits a protective action against the neuronal cell death in the parietal cortex and may have a beneficial effect on neurodegenerative disorders such as an Alzheimer-type disease.

Journal

  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 74(3), 285-289, 1997-07-01

    The Japanese Pharmacological Society

References:  15

Cited by:  5

Codes

  • NII Article ID (NAID)
    10008679388
  • NII NACSIS-CAT ID (NCID)
    AA00691188
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    00215198
  • NDL Article ID
    4260362
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-D199
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top